Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

autoimmune pulmonary alveolar proteinosis News | Kisho

Kisho

Not rare diseases news,
news about your rare disease.

Earlier

Exploratory data from the IMPALA-2 trial shows that molgramostim significantly improves exercise distance and duration in patients with autoimmune pulmonary alveolar proteinosis. These findings suggest potential benefits for patient mobility and quality of life.

A recent study highlights the association between pulmonary alveolar proteinosis and the use of ruxolitinib, a JAK inhibitor. This finding may prompt further investigation into the safety profile of ruxolitinib in patients with this rare lung disease.

Recent studies highlight the potential of GM-CSF therapy for treating autoimmune pulmonary alveolar proteinosis, showcasing promising results from clinical trials. These insights could pave the way for new therapeutic strategies in managing this rare lung disease.

A case report highlights the diagnosis of pulmonary alveolar proteinosis in a patient undergoing leuprorelin acetate therapy for ovarian endometrioma. This finding underscores the need for awareness of potential pulmonary complications during treatment.

A new study explores the use of inhaled granulocyte-macrophage colony-stimulating factor for treating autoimmune pulmonary alveolar proteinosis. This research highlights potential therapeutic pathways from understanding the disease's pathogenesis to clinical application.

A new study compares cases of pulmonary alveolar proteinosis across Greece, Türkiye, and Cyprus, providing insights into the disease's prevalence and management in these regions. The findings may inform future research and treatment approaches.

A cohort study published in PubMed investigates the neurodevelopmental profile of children with MARS1-related pulmonary alveolar proteinosis. The findings contribute to understanding the cognitive and developmental challenges faced by these patients.

A case study highlights secondary pulmonary alveolar proteinosis linked to ruxolitinib following bone marrow transplantation, showing transient improvement after discontinuation of the drug. This finding may inform future treatment considerations for patients experiencing similar complications.

Research highlights the potential of targeting the PPAR-γ-ABC transporter axis to improve outcomes in secondary pulmonary alveolar proteinosis caused by indium oxide nanoparticles. This study contributes to understanding therapeutic avenues for this rare lung condition.

A recent study highlights the comorbidity of autoimmune diseases in patients with autoimmune pulmonary alveolar proteinosis. This research may inform future clinical approaches and management strategies for affected individuals.

A case report highlights autoimmune pulmonary alveolar proteinosis induced by brigatinib, contributing to the understanding of drug-related adverse effects. This literature review may inform clinicians about potential risks associated with brigatinib treatment.

A systematic review and meta-analysis evaluates the efficacy and safety of inhaled GM-CSF in treating autoimmune pulmonary alveolar proteinosis. The findings contribute to understanding potential therapeutic options for this rare lung disease.

A recent study published in PubMed discusses a case of pleuroparenchymal fibroelastosis complicated by pulmonary alveolar proteinosis following peripheral blood stem cell transplantation. This research highlights the complexities and potential complications associated with stem cell transplants.

Savara launches an Early Access Program for molgramostim inhalation solution, aimed at patients with Autoimmune Pulmonary Alveolar Proteinosis. This initiative provides critical access to treatment for a rare disease affecting lung function.

Not rare diseases news,news about your rare disease.